Onyx Pharmaceuticals, Inc. today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the American Society of Hematology (ASH) Annual Meeting, December 4-7, 2010, at the Orange County Convention Center in Orlando, FL.
"The accumulating carfilzomib data support its potential as a new treatment option for patients with multiple myeloma, and we are committed to bringing this promising compound to patients as quickly as possible," said Ted W. Love, M.D., Executive Vice President and Head of Research and Development of Onyx Pharmaceuticals. "Based on the full results of the Phase 2b 003-A1 carfilzomib study, which will be presented at ASH, we plan to submit a New Drug Application (NDA) filing for accelerated approval as early as mid-2011."
No comments:
Post a Comment